BlackRock Fund Advisors’s Biogen BIIB Stock Holding History

BlackRock Fund Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.5B	Buy	5,298,451 +329,114	+7%	+$97.6M	0.28%	49
2016 Q3	$1.56B	Buy	4,969,337 +125,890	+3%	+$37.3M	0.32%	46
2016 Q2	$1.17B	Buy	4,843,447 +71,709	+2%	+$18.9M	0.26%	57
2016 Q1	$1.24B	Sell	4,771,738 -383,936	-7%	-$101M	0.29%	52
2015 Q4	$1.58B	Sell	5,155,674 -192,578	-4%	-$55.3M	0.36%	43
2015 Q3	$1.56B	Buy	5,348,252 +725,243	+16%	+$240M	0.4%	35
2015 Q2	$1.87B	Buy	4,623,009 +215,227	+5%	+$86.4M	0.45%	24
2015 Q1	$1.86B	Sell	4,407,782 -126,812	-3%	-$50M	0.44%	22
2014 Q4	$1.54B	Buy	4,534,594 +602,854	+15%	+$195M	0.38%	34
2014 Q3	$1.3B	Buy	3,931,740 +168,931	+4%	+$55.7M	0.37%	35
2014 Q2	$1.19B	Sell	3,762,809 -108,049	-3%	-$32.5M	0.33%	34
2014 Q1	$1.18B	Buy	3,870,858 +348,287	+10%	+$111M	0.35%	33
2013 Q4	$985M	Sell	3,522,571 -107,721	-3%	-$27.9M	0.3%	42
2013 Q3	$874M	Buy	3,630,292 +466,300	+15%	+$104M	0.3%	42
2013 Q2	$681M	Buy	+3,163,992	New	+$676M	0.25%	50

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BlackRock Fund Advisors's BIIB Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Biogen (BIIB) stake by 6.6% in Q4 2016, buying an estimated $97.6M and bringing the position to 5,298,451 shares worth $1.5B. The position accounts for 0.28% of the portfolio, ranked #49.

BlackRock Fund Advisors first reported a position in BIIB in Q2 2013 and has held it in 15 quarters since. The position peaked at $1.87B in Q2 2015. 1,026 funds tracked by Wall St. Rank hold BIIB as of Q4 2016.

BlackRock Fund Advisors held 5,298,451 shares of Biogen worth $1.5B as of Q4 2016.
BlackRock Fund Advisors bought 329,114 Biogen shares in Q4 2016, an estimated $97.6M.
Biogen made up 0.28% of BlackRock Fund Advisors's portfolio in Q4 2016, its #49 holding.
BlackRock Fund Advisors first reported a position in Biogen in Q2 2013 and has held it in 15 quarters since.
BlackRock Fund Advisors's Biogen position peaked at $1.87B in Q2 2015.
1,026 funds tracked by Wall St. Rank held Biogen as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.